logo
HHS under Kennedy might be moving to undercut lifesaving preventive care

HHS under Kennedy might be moving to undercut lifesaving preventive care

Washington Post18-07-2025
The U.S. Preventive Services Task Force is a tiny independent advisory group that most Americans probably have never heard of. But there's a good chance that you might live longer — or even be alive today — thanks to the work it has done.
Created in 1984, this panel of 16 experts, housed within the Department of Health and Human Services, works on a volunteer basis to evaluate scientific evidence in more than 90 areas where preventive medicine can make a difference and offers recommendations for primary care clinicians to follow. The topics the task force studies are as varied as preventive medications (Does taking low-dose aspirin stave off cardiovascular disease?), screenings for mental and physical illnesses (At what age should women start getting mammograms?), and domestic violence (How can clinicians help find patients who are being abused by an intimate partner?).
With the passage of the Affordable Care Act in 2010, the task force's role became dramatically more significant; a provision of that law requires that insurance companies cover the total cost of any preventive care that receives an A or a B grade from the task force. KFF, a leading health research organization, estimates that, as a result, 100 million privately insured people a year get preventive services without having to pay out of pocket.
The members of the task force meet in person only three times a year, and one of those sessions was supposed to happen on July 10. That meeting was abruptly canceled and has yet to be rescheduled — which has set off alarm bells about what, in the words of Sen. Patty Murray (D-Washington), former chair of the Senate Health Committee, 'our conspiracy-promoting Health Secretary is up to next.'
Specifically, the worry is that Secretary Robert F. Kennedy Jr. is planning a move similar to his ouster of the 17 vaccine experts who sat on the Advisory Committee on Immunization Practices, an independent panel that is part of the Centers for Disease Control and Prevention. Kennedy is a noted vaccine skeptic, and a longtime critic of the advisory panel.
More than 100 health organizations have signed a letter to key members of Congress urging them to protect the independence and integrity of the task force 'from intentional or unintentional political interference,' noting: 'The loss of trustworthiness in the rigorous and nonpartisan work of the Task Force would devastate patients, hospital systems, and payers as misinformation creates barriers to accessing lifesaving and cost effective care.'
The move by HHS comes in the wake of the Supreme Court's June 27 decision in Kennedy v. Braidwood Management Inc., in which the justices ruled against a group of Christian-owned businesses and individuals challenging the constitutionality of the task force's role in mandating what private insurance policies cover. Specifically, the plaintiffs raised religious objections to being required to buy health insurance that covers task force-recommended measures such as PrEP (pre-exposure prophylaxis) to prevent HIV transmission and screenings for sexually transmitted disease.
The court ruled on somewhat technical grounds. It considered whether the process for selecting task force members, which is done by the HHS secretary, violated the Constitution's clause requiring that 'Officers of the United States' be appointed by the president and are subject to Senate confirmation.
The Trump administration, surprising some, sided with the Biden administration's argument that the task force consists of 'inferior officers' not covered under the appointments clause. But in the brief it filed in the case, the current administration added the additional claim that this meant the HHS secretary has the power to 'remove Task Force members at will, for any reason' and to overrule their recommendations.
Currently, members serve four-year terms, staggered so that each year, one-fourth of the task force is replaced. The structure helps assure that it remains independent and nonpartisan, Aaron Carroll, the president of AcademyHealth, a leading health research and policy organization, told me. To upend it, he said, would send 'a chilling message, and it opens the door to a lot of fringe theories.'
As I've written before, the real problem with the task force is that it has almost no staff and lacks the resources to keep up with the lifesaving advances that science is making. It can take years and even a decade between the time the Food and Drug Administration approves a new screening method, such as the one it green-lit last year for a simple blood test to find colorectal cancer, and when the panel gives its assessment of the test's efficacy. In the meantime, people are suffering and even dying because their disease was not caught in its early stages, when it is more curable.
Thus far, the limbo into which the task force has been placed has not received as much attention as it deserves. I have not gotten a response to my own query to HHS asking for an explanation of why its meeting was canceled and whether there are any changes planned for the role or the membership of the task force.
Is the Trump administration moving to undercut the Affordable Care Act's promise that health insurance would provide access to the most scientifically sound preventive care? Americans deserve an answer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Self-Management Asthma App Boosts Symptom Control in Adults
Self-Management Asthma App Boosts Symptom Control in Adults

Medscape

time4 minutes ago

  • Medscape

Self-Management Asthma App Boosts Symptom Control in Adults

TOPLINE: In adults with asthma, a digital asthma self-management (DASM) program improved symptom control compared with usual care, although its effectiveness varied by race, with weaker results observed among African American participants. METHODOLOGY: Researchers conducted a randomized trial to evaluate the impact of a DASM program on symptom control among adults with asthma. A total of 899 participants (mean age, 36.6 years; 71.1% women; approximately 61.3% with uncontrolled asthma) were recruited via email between October 2020 and November 2021 to receive either the DASM program (n = 450) or usual care (n = 449). All the enrolled participants installed a custom smartphone app and utilized wearable devices during the trial. The DASM group received a full-featured self-management version with symptom tracking and alerts, whereas the usual care group received a limited version with only the asthma control test and collection of patient-reported outcomes. The primary outcomes included the 12-month change from baseline in asthma control test scores (scores ≤ 19 indicated uncontrolled asthma), and secondary outcomes included participants' counts of symptom logs and patient-reported outcomes. TAKEAWAY: Among participants with uncontrolled asthma, the DASM intervention improved mean asthma control test scores by 4.6 points at 12 months compared with a 1.8-point improvement with usual care (adjusted difference, 2.8 points; P < .001). The treatment effect varied by race, with between-group differences in asthma control test scores showing improvements of 1.0 point (P = .26) in African American participants and 3.3 points (P < .001) in non-African American participants. Symptom logging rates were comparable across insurance and ethnicity subgroups, with no significant differences observed. However, African American participants logged symptoms less frequently than non-African American participants. Patient-reported outcomes — self-reported medication adherence, readiness to change self-management behaviors, confidence in the ability to manage one's health, and asthma-related work productivity impairment — also favored the DASM intervention over usual care (P ≤ .001 for all). IN PRACTICE: 'Findings reveal an opportunity to adapt the DASM program for more consistent effects throughout diverse populations. Future research is needed — quantitative and qualitative — to elucidate causes of differences in outcomes,' the authors wrote. SOURCE: The study was led by Jordan Silberman, MD, PhD, Office of Medical Policy and Technology Assessment, Elevance Health, Palo Alto, California. It was published online on July 17, 2025, in JAMA Network Open. LIMITATIONS: The study was limited by the requirement for iPhone ownership, exclusion of uninsured participants, lack of blinding, and potential for biased missingness despite robust sensitivity analyses. DISCLOSURES: This study was funded by Elevance Health, Inc. (formerly Anthem Inc.), with support from Apple Inc. Three authors declared receiving financial support from Apple or grants from Elevance Health. One author reported receiving stock from Elevance Health. Few other authors reported receiving financial aid from the University of California and pharmaceutical companies, including Pfizer, AstraZeneca, and Eli Lilly and Company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Trump Administration Halts NIH From Issuing Any New Research Grants
Trump Administration Halts NIH From Issuing Any New Research Grants

Forbes

time5 minutes ago

  • Forbes

Trump Administration Halts NIH From Issuing Any New Research Grants

The White House Office of Management and Budget (OMB), led by Director Russell Vought (C) seen here ... More with U.S. President Donald Trump (L), is reportedly blocking the National Institutes of Health from issuing any new funding to grantees and contractors. (Photo by ANDREW CABALLERO-REYNOLDS/AFP via Getty Images) Things just got even tougher for science and scientists around the country and the countless patients and other people that their research could eventually benefit. For the past several months, many researchers in the U.S. have already had to deal with kind of a 'cancel culture' with their grants from the National Institutes of Health being abruptly held, cut or terminated if certain words, phrases or concepts appeared in them that didn't correspond with what the Trump Administration wanted. And now the Trump Administration is putting an immediate 'pause' on the NIH's ability to issue any new research grants, contracts or training awards to anyone outside the NIH. The OMB Blocks The NIH From Providing New Funding Yep, Angus Chen, Megan Molteni, and Anil Oza just reported for STAT how this directive came out of the White House Office of Management and Budget and was delivered as a four-sentence email to the directors of NIH institutes and centers on Tuesday afternoon. The email referred to a 'footnote' from the OMB regarding funding for the NIH and indicated that the U.S. Department of Health and Human Services 'has interpreted this footnote' to mean that new funding from the NIH would be prohibited for now but the NIH is 'working to make this limitation short-term and temporary.' That footnote could end up being quite a kick to the rears of grantees, awardees and contractors in universities, medical centers and other research organizations around the country. It looks like any researcher expecting to receive funds from the NIH through either new awards or renewals of current awards may have to wait for it, wait for it, wait until who knows what needs to happen. Neither the OMB nor the NIH have clarified what will happen and what needs to happen to make funding available again. (I am reaching out to contacts at HHS and NIH for further comment.) This situation basically further handcuffs the NIH's ability to use money that Congress already allocated to the NIH to use this fiscal year. It's kind of like of your parents giving you an allowance and then someone else saying, 'Oh you can't use that.' NIH Employees Prohibited From Spending Money On Purchases Or Travel The OMB footnote will do some further kicking to those working within the NIH as well. That is those still working within the NIH. Since U.S. President Donald Trump took office, there have been multiple waves of different Rs at the NIH. And these Rs haven't exactly been rest and relaxation. They've been rounds of resignations, retirements and RIFs—meaning reductions in force. The remaining NIH employees will reportedly not be able to spend any more money on purchases or travel until the end of the current government fiscal year, which will be September 30. Unspent NIH Funds Would Return To The U.S. Treasury After September 30 Speaking of the government fiscal year. Being only two months away from its end raises an even bigger concern. If this situation isn't 'short-term' and 'temporary' enough, it could soon become quite permanent. Once September 30 passes, money unspent by the NIH would automatically go back to the U.S. Treasury. So, in two months, researchers might have to sing 'bye-bye-bye' to the funding they thought they would receive. That certanly wouldn't be in sync with any of their staffing and scientific plans. This so-called 'temporary' situation could be a way of cutting NIH funding in a manner that bypasses Congress. This office of Senator Patty Murray (D-Washington) has estimated that the funds currently hanging in the balance may total around $15 billion. NIH Funding Halt May Cause Even More Job Loss I've written previously in Forbes about how the cutting and canceling of research grants will cause job loss. Unless we've entered some other world in the multi-verse, that still hold. Many scientists depend on NIH funding to pay their own salaries and fringe benefits as well those of their research staffs. When it's not clear when and if expected funding will arrive, there's only so long researchers can hold on, in the words of Wilson Phillips, before they have to lay off people or even lose their own positions. And once a researcher or research staff member is lost, it can be tough to replace them. It's not as if you are simply looking for something to post something dumb on social media or be featured in the reality TV show 'Cheaters.' The U.S. doesn't have an unlimited supply of those with appropriate scientific talent, skills and drive. It can take a lot of time to find someone with the right stuff to fill a position. You can't simply tell the coaches or managers of the Los Angeles Dodgers, Philadelphia Eagles or Oklahoma City Thunder, 'Yeah, we know that you have been sort of successful. But we won't allow you to pay your players, so you are going to have to cut them. Oh, but don't worry, some day when you do have money, we aren't saying when and how, you can always find new players.' NIH Funding Halt Will Have Widespread Ramifcations On Health And The Economy If you don't do any scientific research and think this NIH funding halt won't affect you, think again. It's not as if the NIH funded researchers out there are spending their days posting random rants on social media. They are working hard, often day and night, on ways to prevent and treat different disease such as cardiovascular disease, diabetes, obesity, cancer and a whole range of different infectious diseases, including those that may cause the 'p' word some day. Who knows how many lives will end being affected by these interruptions, disruptions and stoppages of such work? And no matter how healthy you think you are right now, no matter how much kombucha, eyes of newt or whatever you are consuming right now, you will run into health problems some day. You, your family members and your friends will. Trying to keep as many Americans as healthy as possible shouldn't be a political thing. More Americans being healthy longer would mean more Americans to work and produce for society longer. That should be a win-win situation. Or a win-win-win situation. More legit biomedical and health research as opposed to more let's-just-say-it-happens-woo-woo should help the economy as well. More science-backed stuff would mean more stable and sustainable health products and interventions that can form the basis of more sustainable businesses. Yet, this 'pause' in NIH funding is yet another blow to science, scientific research and all of the above. It should give everyone pause to think about what's really important for this country and whether things are headed in the right direction in U.S. After all, this latest 'temporary' situation with NIH may not end up being temporary at all.

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Associated Press

time5 minutes ago

  • Associated Press

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval[1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases[2] to date in 2025. A Measles holiday warning has been issued in the UK this year[3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF)[4] . Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO[5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine[6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store